Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548.
Kähkönen E, Jambor I, Kemppainen J, Lehtiö K, Grönroos TJ, Kuisma A, Luoto P, Sipilä HJ, Tolvanen T, Alanen K, Silén J, Kallajoki M, Roivainen A, Schäfer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H. Kähkönen E, et al. Among authors: kuisma a. Clin Cancer Res. 2013 Oct 1;19(19):5434-43. doi: 10.1158/1078-0432.CCR-12-3490. Epub 2013 Aug 9. Clin Cancer Res. 2013. PMID: 23935037 Free article.
Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H, Saunavaara J, Noponen T, Minn H, Aronen HJ, Seppänen M. Jambor I, et al. Among authors: kuisma a. Acta Oncol. 2016;55(1):59-67. doi: 10.3109/0284186X.2015.1027411. Epub 2015 Apr 2. Acta Oncol. 2016. PMID: 25833330
Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).
Jambor I, Kuisma A, Kähkönen E, Kemppainen J, Merisaari H, Eskola O, Teuho J, Perez IM, Pesola M, Aronen HJ, Boström PJ, Taimen P, Minn H. Jambor I, et al. Among authors: kuisma a. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):355-364. doi: 10.1007/s00259-017-3875-1. Epub 2017 Nov 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29147764 Clinical Trial.
Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI.
Movahedi P, Merisaari H, Perez IM, Taimen P, Kemppainen J, Kuisma A, Eskola O, Teuho J, Saunavaara J, Pesola M, Kähkönen E, Ettala O, Liimatainen T, Pahikkala T, Boström P, Aronen H, Minn H, Jambor I. Movahedi P, et al. Among authors: kuisma a. Sci Rep. 2020 Jun 10;10(1):9407. doi: 10.1038/s41598-020-66255-8. Sci Rep. 2020. PMID: 32523075 Free PMC article. Clinical Trial.
Uptake of 18F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study.
Malaspina S, Taimen P, Kallajoki M, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Malaspina S, et al. Among authors: kuisma a. Cancer Biother Radiopharm. 2022 Apr;37(3):205-213. doi: 10.1089/cbr.2021.0322. Epub 2021 Dec 28. Cancer Biother Radiopharm. 2022. PMID: 34962139 Clinical Trial.
Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.
Saarinen I, Jambor I, Kim M, Kuisma A, Kemppainen J, Merisaari H, Eskola O, Koskenniemi AR, Perez IM, Boström P, Taimen P, Minn H. Saarinen I, et al. Among authors: kuisma a. EJNMMI Res. 2019 May 31;9(1):50. doi: 10.1186/s13550-019-0518-5. EJNMMI Res. 2019. PMID: 31152256 Free PMC article.
Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer.
Malaspina S, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Malaspina S, et al. Among authors: kuisma a. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3723-3731. doi: 10.1007/s00259-021-05346-8. Epub 2021 Apr 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 33846844 Free PMC article.
Comparison of reprojected bone SPECT/CT and planar bone scintigraphy for the detection of bone metastases in breast and prostate cancer.
Arvola S, Seppänen M, Malaspina S, Mätzke S, Raiko J, Timonen KL, Ettala O, Jambor I, Anttinen M, Kuisma A, Löyttyniemi E, Boström PJ, Sohlberg A, Noponen T. Arvola S, et al. Among authors: kuisma a. Nucl Med Commun. 2022 May 1;43(5):510-517. doi: 10.1097/MNM.0000000000001536. Nucl Med Commun. 2022. PMID: 35081092 Free article.
12 results